Skip to main content

Articles

Page 35 of 61

  1. Patients with type 2 diabetes present with an accelerated atherosclerotic process. Animal evidence indicates that dipeptidyl peptidase-4 inhibitors (gliptins) have anti-inflammatory and anti-atherosclerotic ef...

    Authors: Arwa Younis, Dana Eskenazi, Ronen Goldkorn, Jonathan Leor, Nili Naftali-Shani, Enrique Z. Fisman, Alexander Tenenbaum, Ilan Goldenberg and Robert Klempfner
    Citation: Cardiovascular Diabetology 2017 16:69
    Content type: Original investigation Published on:

  2. In diabetic patients a predisposed coronary microcirculation along with a higher risk of distal particulate embolization during primary percutaneous intervention (PCI) increases the risk of peri-procedural mic...

    Authors: Enrico Cerrato, Alicia Quirós, Mauro Echavarría-Pinto, Hernan Mejia-Renteria, Andres Aldazabal, Nicola Ryan, Nieves Gonzalo, Pilar Jimenez-Quevedo, Luis Nombela-Franco, Pablo Salinas, Iván J. Núñez-Gil, José Ramón Rumoroso, Antonio Fernández-Ortiz, Carlos Macaya and Javier Escaned
    Citation: Cardiovascular Diabetology 2017 16:68
    Content type: Study protocol Published on:

  3. Multiple bloodglucose-lowering agents have been linked to cardiovascular events. Preliminary studies showed improvement in left ventricular (LV) function during glucagon-like peptide-1 receptor agonist adminis...

    Authors: Weena J. Y. Chen, Michaela Diamant, Karin de Boer, Hendrik J. Harms, Lourens F. H. J. Robbers, Albert C. van Rossum, Mark H. H. Kramer, Adriaan A. Lammertsma and Paul Knaapen
    Citation: Cardiovascular Diabetology 2017 16:67
    Content type: Original investigation Published on:

  4. Dyslipidaemia is a major contributor to the increased risk of cardiovascular disease (CVD) associated with type 2 diabetes (T2D). This study aimed to characterize the extent of lipid-lowering therapy use and i...

    Authors: Markolf Hanefeld, Louise Traylor, Ling Gao and Wolfgang Landgraf
    Citation: Cardiovascular Diabetology 2017 16:66
    Content type: Original investigation Published on:

  5. Diabetic kidney disease (DKD) is the most common cause of end stage renal disease. The comprehensive management of DKD depends on combined target-therapies for hyperglycemia, hypertension, albuminuria, and hyp...

    Authors: Honghong Zou, Baoqin Zhou and Gaosi Xu
    Citation: Cardiovascular Diabetology 2017 16:65
    Content type: Review Published on:

    The Correction to this article has been published in Cardiovascular Diabetology 2018 17:38

  6. Recent analyses in a registry of hypertensive patients suggested that preceding left ventricular (LV) hypertrophy (LVH) and/or carotid atherosclerosis are associated with incident type 2 diabetes, independent ...

    Authors: Giovanni de Simone, Wenyu Wang, Lyle G. Best, Fawn Yeh, Raffaele Izzo, Costantino Mancusi, Mary J. Roman, Elisa T. Lee, Barbara V. Howard and Richard B. Devereux
    Citation: Cardiovascular Diabetology 2017 16:64
    Content type: Original investigation Published on:

  7. Diabetes is associated closely with an increased risk of cardiovascular events, including diastolic dysfunction and heart failure that leads to a shortening of life expectancy. It is therefore extremely valuab...

    Authors: Hirotsugu Yamada, Atsushi Tanaka, Kenya Kusunose, Rie Amano, Munehide Matsuhisa, Hiroyuki Daida, Masaaki Ito, Hiroyuki Tsutsui, Mamoru Nanasato, Haruo Kamiya, Yasuko K. Bando, Masato Odawara, Hisako Yoshida, Toyoaki Murohara, Masataka Sata and Koichi Node
    Citation: Cardiovascular Diabetology 2017 16:63
    Content type: Original investigation Published on:

  8. Lipopolysaccharide (LPS)-binding protein (LBP) is an acute-phase reactant that mediates immune responses triggered by LPS. Recent evidence indicates the association of circulating LBP levels with obesity, diab...

    Authors: Takeshi Sakura, Tomoaki Morioka, Atsushi Shioi, Yoshinori Kakutani, Yuya Miki, Yuko Yamazaki, Koka Motoyama, Katsuhito Mori, Shinya Fukumoto, Tetsuo Shoji, Masanori Emoto and Masaaki Inaba
    Citation: Cardiovascular Diabetology 2017 16:62
    Content type: Original investigation Published on:

  9. Diastolic dysfunction (DD), a hallmark of obesity and primary defect in heart failure with preserved ejection fraction, is a predictor of future cardiovascular events. We previously reported that linagliptin, ...

    Authors: Annayya R. Aroor, Javad Habibi, Hemanth Kumar Kandikattu, Mona Garro-Kacher, Brady Barron, Dongqing Chen, Melvin R. Hayden, Adam Whaley-Connell, Shawn B. Bender, Thomas Klein, Jaume Padilla, James R. Sowers, Bysani Chandrasekar and Vincent G. DeMarco
    Citation: Cardiovascular Diabetology 2017 16:61
    Content type: Original investigation Published on:

  11. Authors: Marcus Wiemer, Sinisa Stojkovic, Alexander Samol, Zisis Dimitriadis, Juan M. Ruiz-Nodar, Ralf Birkemeyer, Jacques Monsegu, Gérard Finet, David Hildick-Smith, Damras Tresukosol, Enrique Garcia Novo, Jacques J. Koolen, Emanuele Barbato and Gian Battista Danzi
    Citation: Cardiovascular Diabetology 2017 16:59
    Content type: Erratum Published on:

    The original article was published in Cardiovascular Diabetology 2017 16:23

  13. Sudden cardiac death (SCD), a leading cause of global mortality, most commonly arises from a substrate of cardiac ischemia, but requires an additional trigger. Diabetes mellitus (DM) predisposes to SCD even af...

    Authors: Zhaoyang Hu, Mou Chen, Ping Zhang, Jin Liu and Geoffrey W. Abbott
    Citation: Cardiovascular Diabetology 2017 16:57
    Content type: Original investigation Published on:

  14. Retinal vessel calibre and vascular dilation/constriction in response to flicker light provocation may provide a measure distinguishing patients suffering from diabetes mellitus and/or cardiovascular disease.

    Authors: R. Heitmar, G. Y. H. Lip, R. E. Ryder and A. D. Blann
    Citation: Cardiovascular Diabetology 2017 16:56
    Content type: Original investigation Published on:

  15. Altered regulation of extracellular matrix remodeling by matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinase (TIMP) may contribute to vascular complications in type 1 diabetes. We invest...

    Authors: S. A. Peeters, L. Engelen, J. Buijs, A. Jorsal, H.-H. Parving, L. Tarnow, P. Rossing, C. G. Schalkwijk and C. D. A. Stehouwer
    Citation: Cardiovascular Diabetology 2017 16:55
    Content type: Original investigation Published on:

  16. Although central fat is a well-known risk factor for cardiovascular disease (CVD) and cardiometabolic disorders, the effect of other regional fats or muscle distribution on CVD risk has not been fully investig...

    Authors: Eugene Han, Yong-ho Lee, Byung-Wan Lee, Eun Seok Kang, In-Kyu Lee and Bong-Soo Cha
    Citation: Cardiovascular Diabetology 2017 16:54
    Content type: Original investigation Published on:

  17. Authors: Kirstie A. De Jong, Juliane K. Czeczor, Smithamol Sithara, Kevin McEwen, Gary D. Lopaschuk, Alan Appelbe, Kimberly Cukier, Mark Kotowicz and Sean L. McGee
    Citation: Cardiovascular Diabetology 2017 16:53
    Content type: Erratum Published on:

    The original article was published in Cardiovascular Diabetology 2017 16:21

  18. Advanced glycation end-products (AGEs) are elevated under diabetic conditions and associated with insulin resistance, endothelial dysfunction and vascular inflammation in humans. It has been demonstrated that ...

    Authors: Xiaomei Ren, Liqun Ren, Qin Wei, Hua Shao, Long Chen and Naifeng Liu
    Citation: Cardiovascular Diabetology 2017 16:52
    Content type: Original investigation Published on:

  19. Diabetes mellitus (DM) is associated with an excess in cardiovascular morbidity and mortality, and is characterized by increased rates of coronary artery disease. Furthermore, once atherosclerosis is establish...

    Authors: Mark W. Kennedy, Enrico Fabris, Harry Suryapranata and Elvin Kedhi
    Citation: Cardiovascular Diabetology 2017 16:51
    Content type: Review Published on:

  20. Despite numerous studies on cardioprotective effects of omega-3 polyunsaturated fatty acids (n-3 PUFAs), there is limited evidence for n-3 PUFA-mediated effects, especially at its higher dose, on cardiovascula...

    Authors: Malgorzata Poreba, Magdalena Mostowik, Aleksander Siniarski, Renata Golebiowska-Wiatrak, Krzysztof Piotr Malinowski, Maciej Haberka, Ewa Konduracka, Jadwiga Nessler, Anetta Undas and Grzegorz Gajos
    Citation: Cardiovascular Diabetology 2017 16:50
    Content type: Original investigation Published on:

  21. Gestational diabetes mellitus (GDM) has significant implications for the future health of the mother. Some clinical studies have suggested subclinical inflammation and vascular dysfunction after GDM. We aimed ...

    Authors: Tiina Vilmi-Kerälä, Anneli Lauhio, Taina Tervahartiala, Outi Palomäki, Jukka Uotila, Timo Sorsa and Ari Palomäki
    Citation: Cardiovascular Diabetology 2017 16:49
    Content type: Original investigation Published on:

  22. Type 2 diabetes mellitus (T2DM) is characterized by systemic metabolic abnormalities and the development of micro- and macrovascular complications, resulting in a shortened life expectancy. A recent cardiovasc...

    Authors: Atsushi Tanaka, Michio Shimabukuro, Yosuke Okada, Isao Taguchi, Minako Yamaoka-Tojo, Hirofumi Tomiyama, Hiroki Teragawa, Seigo Sugiyama, Hisako Yoshida, Yasunori Sato, Atsushi Kawaguchi, Yumi Ikehara, Noritaka Machii, Tatsuya Maruhashi, Kosuke R. Shima, Toshinari Takamura…
    Citation: Cardiovascular Diabetology 2017 16:48
    Content type: Study protocol Published on:

  23. Disturbances in coronary microcirculatory function, such as the endothelial glycocalyx, are early hallmarks in the development of obesity and insulin resistance. Accordingly, in the present study myocardial mi...

    Authors: Judith van Haare, M. Eline Kooi, Jurgen W. G. E. van Teeffelen, Hans Vink, Jos Slenter, Hanneke Cobelens, Gustav J. Strijkers, Dennis Koehn, Mark J. Post and Marc van Bilsen
    Citation: Cardiovascular Diabetology 2017 16:47
    Content type: Original investigation Published on:

    The Correction to this article has been published in Cardiovascular Diabetology 2021 20:53

  24. Ribonuclease-L (RNase-L) was known to be a ubiquitous enzyme involved in several cellular functions, especially innate immunity. It was recently shown to participate in adipogenesis in rodents. Here, we develo...

    Authors: Yi-Ting Wang, Ping-Huei Tseng, Chi-Ling Chen, Der-Sheng Han, Yu-Chiao Chi, Fen-Yu Tseng and Wei-Shiung Yang
    Citation: Cardiovascular Diabetology 2017 16:46
    Content type: Original investigation Published on:

  25. The risk prediction of pregnancy-associated plasma protein-A (PAPP-A) for future cardiovascular (CV) events post acute coronary syndrome (ACS) in patients with type-2 diabetes mellitus (T2DM) was investigated ...

    Authors: Wei-Ping Li, Moni B. Neradilek, Fu-Sheng Gu, Daniel A. Isquith, Zhi-Jun Sun, Xing Wu, Hong-Wei Li and Xue-Qiao Zhao
    Citation: Cardiovascular Diabetology 2017 16:45
    Content type: Original investigation Published on:

  26. Nowadays, obesity is seriously increasing in most of the populations all over the world, and is associated with the development and progression of high-mortality diseases such as type-2 diabetes mellitus (T2DM) a...

    Authors: N. González, Z. Moreno-Villegas, A. González-Bris, J. Egido and Ó. Lorenzo
    Citation: Cardiovascular Diabetology 2017 16:44
    Content type: Review Published on:

  27. While acute hyperglycemia has been shown to mitigate the beneficial effects of ischemic preconditioning, its effect on insulin-induced preconditioning remains unclear.

    Authors: Yosuke Nakadate, Hiroaki Sato, Takeshi Oguchi, Tamaki Sato, Akiko Kawakami, Tadahiko Ishiyama, Takashi Matsukawa and Thomas Schricker
    Citation: Cardiovascular Diabetology 2017 16:43
    Content type: Original investigation Published on:

  28. Sodium-glucose co-transporter-2 inhibitors (SGLT2i) reduce glucose levels, body weight, and blood pressure, possibly resulting in cardiovascular protection. In phase III trials, SGLT2i were shown to increase H...

    Authors: Gian Paolo Fadini, Benedetta Maria Bonora, Giancarlo Zatti, Nicola Vitturi, Elisabetta Iori, Maria Cristina Marescotti, Mattia Albiero and Angelo Avogaro
    Citation: Cardiovascular Diabetology 2017 16:42
    Content type: Original investigation Published on:

  29. Patients with diabetes concomitant to critical limb ischemia (CLI) represent a sub-group at particular risk. Objective of this analysis is to evaluate the actual impact of diabetes on treatment, outcome, and c...

    Authors: Eva Freisinger, Nasser M. Malyar, Holger Reinecke and Holger Lawall
    Citation: Cardiovascular Diabetology 2017 16:41
    Content type: Original investigation Published on:

  30. Treatment of patients with type 2 diabetes mellitus (T2DM) and a history of cardiovascular (CV) disease or CV risk factors may present clinical challenges due to the presence of comorbid conditions and the use...

    Authors: Michael J. Davies, Katherine Merton, Ujjwala Vijapurkar, Jacqueline Yee and Rong Qiu
    Citation: Cardiovascular Diabetology 2017 16:40
    Content type: Original investigation Published on:

  31. Obstructive sleep apnea (OSA) and type 2 diabetes (T2D) are associated with endothelial dysfunction a main predictor of late cardiovascular (CV) events. Despite the high prevalence of OSA in patients with T2D,...

    Authors: Vanessa Bironneau, François Goupil, Pierre Henri Ducluzeau, Marc Le Vaillant, Pierre Abraham, Samir Henni, Séverine Dubois, Audrey Paris, Pascaline Priou, Nicole Meslier, Claire Sanguin, Wojciech Trzépizur, Ramaroson Andriantsitohaina, Maria Carmen Martinez and Frédéric Gagnadoux
    Citation: Cardiovascular Diabetology 2017 16:39
    Content type: Original investigation Published on:

  32. We aimed to (1) assess the association between lipoprotein(a) [Lp(a)] concentration and incident type-2 diabetes in the Bruneck study, a prospective population-based study, and (2) combine findings with eviden...

    Authors: Ellie Paige, Katya L. Masconi, Sotirios Tsimikas, Florian Kronenberg, Peter Santer, Siegfried Weger, Johann Willeit, Stefan Kiechl and Peter Willeit
    Citation: Cardiovascular Diabetology 2017 16:38
    Content type: Original investigation Published on:

  33. To establish if aerobic exercise training is associated with beneficial effects on clinical outcomes and glycaemic profile in people with type II diabetes.

    Authors: Aimee Grace, Erick Chan, Francesco Giallauria, Petra L. Graham and Neil A. Smart
    Citation: Cardiovascular Diabetology 2017 16:37
    Content type: Original investigation Published on:

  34. Subclinical left ventricular (LV) diastolic dysfunction in type 2 diabetes (T2D) is a common finding and represents an early sign of diabetic cardiomyopathy. However, the relationship between LV diastolic dysf...

    Authors: Juri Park, Jin-Seok Kim, Seong Hwan Kim, Sunwon Kim, Sang Yup Lim, Hong-Euy Lim, Goo-Yeong Cho, Ki-Chul Sung, Jang-Young Kim, Inkyung Baik, Kwang Kon Koh, Jung Bok Lee, Seung Ku Lee and Chol Shin
    Citation: Cardiovascular Diabetology 2017 16:36
    Content type: Original investigation Published on:

  35. The 2nd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes and Cardiovascular Disease (D&CVD) EASD Study Group was held on the 20th–21st October 2016 in Munich. This second Summit was organized in ligh...

    Authors: Oliver Schnell, Eberhard Standl, Doina Catrinoiu, Stefano Genovese, Nebojsa Lalic, Jan Skra, Paul Valensi, Dario Rahelic and Antonio Ceriello
    Citation: Cardiovascular Diabetology 2017 16:35
    Content type: Commentary Published on:

    The Correction to this article has been published in Cardiovascular Diabetology 2017 16:135

  36. An enhanced thrombotic environment and premature atherosclerosis are key factors for the increased cardiovascular risk in diabetes. The occlusive vascular thrombus, formed secondary to interactions between pla...

    Authors: Katherine Kearney, Darren Tomlinson, Kerrie Smith and Ramzi Ajjan
    Citation: Cardiovascular Diabetology 2017 16:34
    Content type: Review Published on:

  37. Vascular dysfunction is a pivotal event in the development of diabetes-associated vascular disease. Increased inflammation and oxidative stress are major contributors to vascular dysfunction. Nrf2, a master re...

    Authors: Arpeeta Sharma, Luddwi Rizky, Nada Stefanovic, Mitchel Tate, Rebecca H. Ritchie, Keith W. Ward and Judy B. de Haan
    Citation: Cardiovascular Diabetology 2017 16:33
    Content type: Original investigation Published on:

  38. Accumulation of epicardial fat (EF) is associated with increased cardio-metabolic risks and coronary events, independently of traditional cardiovascular risk factors. Therefore, the reduction of EF volume (EFV...

    Authors: Ryotaro Bouchi, Masahiro Terashima, Yuriko Sasahara, Masahiro Asakawa, Tatsuya Fukuda, Takato Takeuchi, Yujiro Nakano, Masanori Murakami, Isao Minami, Hajime Izumiyama, Koshi Hashimoto, Takanobu Yoshimoto and Yoshihiro Ogawa
    Citation: Cardiovascular Diabetology 2017 16:32
    Content type: Original investigation Published on:

  39. Incretin-based agents, including dipeptidyl peptidase-4 inhibitors (DPP-4Is) and glucagon-like peptide-1 agonists (GLP-1As), work via GLP-1 receptor for hyperglycemic control directly or indirectly, but have d...

    Authors: Zeqing Zhang, Xi Chen, Puhan Lu, Jianhua Zhang, Yongping Xu, Wentao He, Mengni Li, Shujun Zhang, Jing Jia, Shiying Shao, Junhui Xie, Yan Yang and Xuefeng Yu
    Citation: Cardiovascular Diabetology 2017 16:31
    Content type: Original investigation Published on:

  40. Risk of type 2 diabetes mellitus (T2DM) is increased in metabolically obese but normal-weight people. However, we have limited knowledge of how to prevent T2DM in normal-weight people. We aimed to evaluate the...

    Authors: Ming Zhang, Bingyuan Wang, Yu Liu, Xizhuo Sun, Xinping Luo, Chongjian Wang, Linlin Li, Lu Zhang, Yongcheng Ren, Yang Zhao, Junmei Zhou, Chengyi Han, Jingzhi Zhao and Dongsheng Hu
    Citation: Cardiovascular Diabetology 2017 16:30
    Content type: Original investigation Published on:

  41. Physiologic determinants, such as pulse pressure [difference between systolic blood pressure (SBP) and diastolic BP (DBP)], mean arterial pressure (2/3 DBP + 1/3 SBP), and double product [beats per minute (bpm...

    Authors: Michael Pfeifer, Raymond R. Townsend, Michael J. Davies, Ujjwala Vijapurkar and Jimmy Ren
    Citation: Cardiovascular Diabetology 2017 16:29
    Content type: Original article Published on:

  42. Diabetic cardiomyopathy (DCM) is a cardiac dysfunction which affects approximately 12% of diabetic patients, leading to overt heart failure and death. However, there is not an efficient and specific methodolog...

    Authors: A. Lorenzo-Almorós, J. Tuñón, M. Orejas, M. Cortés, J. Egido and Ó. Lorenzo
    Citation: Cardiovascular Diabetology 2017 16:28
    Content type: Review Published on:

  43. Fewer circulating endothelial progenitor cells (EPCs) and increased plasma (C-term) stromal cell-derived factor 1α (SDF-1α), a substrate of DPP-4, are biomarkers, and perhaps mediators, of cardiovascular risk ...

    Authors: Alessandra Dei Cas, Valentina Spigoni, Monia Cito, Raffaella Aldigeri, Valentina Ridolfi, Elisabetta Marchesi, Michela Marina, Eleonora Derlindati, Rosalia Aloe, Riccardo C. Bonadonna and Ivana Zavaroni
    Citation: Cardiovascular Diabetology 2017 16:27
    Content type: Original investigation Published on:

  44. The sodium–glucose cotransporter 2 inhibitor, dapagliflozin, has been shown to improve diabetic control and reduce blood pressure in patients with type 2 diabetes mellitus. Its effects on micro- and macrovascu...

    Authors: Christian Ott, Agnes Jumar, Kristina Striepe, Stefanie Friedrich, Marina V. Karg, Peter Bramlage and Roland E. Schmieder
    Citation: Cardiovascular Diabetology 2017 16:26
    Content type: Original article Published on:

  46. Vascular calcification (VC) is common in type 2 diabetes, and is associated with cardiovascular complications. Recent preclinical data suggest that metformin inhibits VC both in vitro and in animal models. How...

    Authors: Aurélien Mary, Agnes Hartemann, Sophie Liabeuf, Carole Elodie Aubert, Salim Kemel, Joe Elie Salem, Philippe Cluzel, Aurélie Lenglet, Ziad A. Massy, Jean-Daniel Lalau, Romuald Mentaverri, Olivier Bourron and Saïd Kamel
    Citation: Cardiovascular Diabetology 2017 16:24
    Content type: Original article Published on:

  47. To report the long-term safety and efficacy data of a third generation drug eluting stent (DES) with biodegradable polymer in the complex patient population of diabetes mellitus after a follow-up period of 5 ...

    Authors: Marcus Wiemer, Sinisa Stoikovic, Alexander Samol, Zisis Dimitriadis, Juan M. Ruiz-Nodar, Ralf Birkemeyer, Jacques Monsegu, Gérard Finet, David Hildick-Smith, Damras Tresukosol, Enrique Garcia Novo, Jacques J. Koolen, Emanuele Barbato and Gian Battista Danzi
    Citation: Cardiovascular Diabetology 2017 16:23
    Content type: Original investigation Published on:

    The Erratum to this article has been published in Cardiovascular Diabetology 2017 16:59

  48. Use of dipeptidyl peptidase-4 inhibitors (DPP4-i) for the treatment of type 2 diabetes (T2D) has been associated with a possible increase in the risk for heart failure (HF). B-type natriuretic peptide (BNP), w...

    Authors: Gian Paolo Fadini, Benedetta Maria Bonora, Mattia Albiero, Martina Zaninotto, Mario Plebani and Angelo Avogaro
    Citation: Cardiovascular Diabetology 2017 16:22
    Content type: Original investigation Published on:

  49. It is unclear whether obesity and type 2 diabetes (T2D), either alone or in combination, induce left ventricular hypertrophy (LVH) independent of hypertension. In the current study, we provide clarity on this ...

    Authors: Kirstie A. De Jong, Juliane K. Czeczor, Smithamol Sithara, Kevin McEwen, Gary D. Lopaschuk, Alan Appelbe, Kimberly Cukier, Mark Kotowicz and Sean L. McGee
    Citation: Cardiovascular Diabetology 2017 16:21
    Content type: Original investigation Published on:

    The Erratum to this article has been published in Cardiovascular Diabetology 2017 16:53

  50. Brain-derived neurotrophic factor (BDNF) exerts beneficial effects not only on diabetic neuropathies but also on cardiovascular injury. There is argument regarding the levels of serum BDNF in patients with dia...

    Authors: Kazuo Furukawa, Ichiro Fuse, Yuriko Iwakura, Hidekazu Sotoyama, Osamu Hanyu, Hiroyuki Nawa, Hirohito Sone and Nobuyuki Takei
    Citation: Cardiovascular Diabetology 2017 16:20
    Content type: Original investigation Published on:
journal logo

Cardiovascular Diabetology is affiliated with Sackler Faculty of Medicine, Tel-Aviv University

New Content Item

Submit manuscript

Annual Journal Metrics

  • 2022 Citation Impact
    9.3 - 2-year Impact Factor
    9.6 - 5-year Impact Factor
    2.054 - SNIP (Source Normalized Impact per Paper)
    2.361 - SJR (SCImago Journal Rank)

    2023 Speed
    4 days submission to first editorial decision for all manuscripts (Median)
    56 days submission to accept (Median)

    2023 Usage 
    2,523,778 downloads
    3,115 Altmetric mentions 

Cardiovascular Diabetology

ISSN: 1475-2840